News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF


6/17/2013 9:22:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)-- New long-term data from the RELY-ABLE® study, the long-term extension of the pivotal RE-LY®i trial of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation (AF), were today published online in Circulation,1 the journal of the American Heart Association. Pradaxa® is the only treatment among the new generation of direct oral anticoagulants, which has been evaluated in a large set of AF patients for more than four years.1 The long-term results reinforce the safety profile of Pradaxa®, which was originally established in the landmark RE-LY® trial.1,2,3

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES